Saturday 17 October 2026
Export MGRX’s income statement to Excel — free account
Mangoceuticals, Inc.
MGRX Healthcare Health Information Services
Mangoceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $456,000.00, down 26.0% from fiscal 2024. In the quarter to June 2026, revenue fell 59.1%, EPS grew 84.2% and free cash flow grew 79.3%, each against the same quarter a year earlier.
0.30
0.02
−6.25%
Follow MGRX
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 3 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | (32.80) | (1.58) | (2.14) |
P/S ratio |
— | 0.00 | 6.39 | 7.78 | 16.34 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (15.40) | (86.95) | 1.97 | 2.42 |
P/Operating CF |
— | (66.48) | (2.75) | (4.24) | (6.91) |
P/B ratio |
— | 70.38 | 6.03 | 0.34 | 0.49 |
Price to Tangible BV |
— | 70.38 | 6.03 | 0.00 | 7.71 |
EV/Sales |
— | 0.00 | 5.38 | 7.68 | 13.08 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (31.57) | (0.56) | (0.97) | (1.02) |
EV/FCF |
— | (31.57) | (0.56) | (0.99) | (1.03) |
Quick Ratio |
0.58 | 2.62 | 3.50 | 0.04 | 1.67 |
Current Ratio |
0.58 | 2.67 | 3.96 | 0.05 | 1.74 |
Net Debt/EBITDA |
1.29 | 0.34 | 0.08 | 0.01 | 0.10 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.02 | 0.71 | 0.08 | 0.03 |
Operating CF/Net income |
0.00 | 0.67 | 0.76 | 0.56 | 0.28 |
Capex/Depreciation |
0.00 | (11.05) | (0.14) | 0.09 | 0.00 |
Interest Coverage |
— | (306.40) | (1,418.29) | (581.90) | (174.23) |
| 0.00% | (669.04%) | (1,326.67%) | (118.29%) | (141.66%) | |
| 0.00% | (389.53%) | (896.98%) | (106.03%) | (131.23%) | |
ROIC |
0.00% | 0.00% | (16,094.45%) | (35.88%) | (82.19%) |
Return on Tangible Assets |
105.99% | (362.30%) | (1,278.79%) | 646.28% | (3,134.38%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 22,431.46% | 1,168.82% | 1,282.38% | 3,667.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.99 | 0.88 |
Share Based Compensation of Revenue |
— | 6,068.54% | 209.25% | 341.99% | 2,350.15% |
Graham Net Nets |
— | 0.01 | 0.12 | (0.28) | 0.09 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (4.62%) | (209.37%) | (200.36%) | (345.95%) |
Free Cash Flow Yield |
— | (3.12%) | (149.82%) | (100.20%) | (77.62%) |
Revenue per Share |
0.00 | 0.01 | 0.68 | 0.31 | 0.05 |
Operating CF per Share |
0.00 | (1.87) | (6.51) | (2.46) | (0.58) |
Capex per Share |
0.00 | (0.06) | 0.00 | 0.03 | 0.00 |
Free Cash Flow per Share |
0.00 | (1.93) | (6.52) | (2.42) | (0.58) |
Cash per Share |
0.00 | 0.95 | 0.69 | 0.03 | 0.15 |
Shareholders Equity per Share |
0.00 | 0.85 | 0.72 | 7.05 | 1.51 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.85 | 0.72 | 7.05 | 1.51 |
Free Cash Flow |
0.00 | (1.39) | (7.00) | (4.80) | (5.85) |
Working Capital |
(0.02) | 0.43 | 0.62 | (1.35) | 0.66 |
Capital Expenditures |
0.00 | (0.04) | 0.00 | 0.07 | — |
Net Current Asset Value |
(0.02) | 0.31 | 0.56 | (1.35) | 0.66 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 4.84 | 0.00 | (0.11) | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
0.00 | 0.03 | 0.26 | 261.25 | 1,646.72 |
Cash ROIC |
0.00% | (107.15%) | (462.47%) | (34.27%) | (35.06%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 3.44 | 0.48 | 0.33 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 3,000.12 | 171.31 | 1,295.84 | 739.76 |
Days of Inventory on Hand |
— | 0.00 | 22.51 | 0.00 | 0.00 |
Average Payables |
— | — | 0.09 | 0.49 | 0.63 |
Average Assets |
— | 0.51 | 1.03 | 8.21 | 15.73 |
Average Common Equity |
— | 0.30 | 0.69 | 7.36 | 14.57 |
Columns are period end dates · fundamentals updated 2 Oct 2026